Fig. 4From: Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profileUnique binding pattern of GenSci059 to CD47. A Protein docking analysis of GenSci059 binding to CD47; B Effect of N-terminal pyroglutamate cyclization on the binding of GenSci059 to CD47; C Pyroglutamate cyclase inhibitor impaired the binding of GenSci059 to the cells; D Effect of CD47 spatial conformation and glycosylation modification of the binding epitope on the binding of GenSci059 to CD47Back to article page